Category Archives: IPR

Stakeholder Intervention at 19th RCEP negotiations round- Chalermsak Kittitrakul, network of PLHIV & AIDS, Peoples’ Health Systems Movement, and FTA Watch

Thai CSOs’ comments on the data exclusivity measure in the RCEP given at the stakeholder consultation meeting hosted by the RCEP trade negotiators at Hyderabad, India on July 25, 2017. Good afternoon, trade negotiators of the ASEAN countries and the … Continue reading

Posted in Data Exclusivity, IPR, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

What’s at stake in Hyderabad

By Feroz Ali, The Hindu | July 28, 2017 India must counter Japan’s U.S.-style pressure at the RCEP talks and ensure affordable generic medicines Leaked texts are like leaked gases — you may never find the one responsible for it, … Continue reading

Posted in Data Exclusivity, IP Rights, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment

Stakeholder Intervention at 19th RCEP negotiations round- James Love, Knowledge Ecology International

These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation. My name is James Love. I work for Knowledge Ecology International, an … Continue reading

Posted in Delinkage, FTA, IPR, Patent, R&D, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

A Trade Deal Could Hit Affordable & Generic Medicines in India. Here’s What You Need to Know.

If accepted the trade deal measures will delay access to affordable medicines by restricting generic competition and maintaining monopoly pricing. Published: The Better India Officials from the sixteen countries negotiating the Regional Comprehensive Economic Partnership (RCEP) trade deal – which … Continue reading

Posted in Data Exclusivity, FTA, Generic competition, Generics, IP Rights, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

US turns screws on India over patent laws

By Nayanima Basu, The Hindu BusinessLine  | JUNE 27, 2017 India’s Intellectual Property Rights (IPR) and patent law enforcement as well New Delhi’s decision to cap prices of medical devices remained a contentious issue with the US even during Prime Minister … Continue reading

Posted in IPR, Patent, Uncategorized, US Pressure | 1 Comment

Many issues on tap for Trump-Modi visit

Source: Politico | June 26, 2017 TRUMP’S CHANCE TO RESET THE INDIA TRADE RELATIONSHIP: Indian Prime Minister Narendra Modi is meeting with President Donald Trump at the White House today, where they are expected to broach a wide-range of issues, … Continue reading

Posted in IPR, Uncategorized, US Pressure | Leave a comment

Intellectual property, affordable medicine, and universal health care

By Dr. Maria Guevara, Business world online| May 05, 2017 MANILA IS SET to host the 18th round of the multilateral trade deal — the Regional Comprehensive Economic Partnership (RCEP) that encompasses 50% of the global population.  With the Philippines … Continue reading

Posted in IPR, Patent, Patents, Regional Comprehensive Economic Partnership, TPP, TRIPS, Uncategorized | Leave a comment